Holen Sie sich die Stockscreener-App
421.47
5.16%
19.67
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st
When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - jammulinksnews.com
How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - jammulinksnews.com
What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - jammulinksnews.com
Does Alnylam Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on momentum-driven investment opportunities - jammulinksnews.com
How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyConsistently superior profits - jammulinksnews.com
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyUnlock powerful stock screening tools today - jammulinksnews.com
How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketCapitalize on strong market momentum - jammulinksnews.com
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastMaximize gains with strategic stock entries - jammulinksnews.com
What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Discover the fastest growing stocks today - jammulinksnews.com
Published on: 2025-08-03 13:52:50 - jammulinksnews.com
What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Exceptional risk-adjusted gains - jammulinksnews.com
Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access - AInvest
Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Is it the right time to buy Alnylam Pharmaceuticals Inc. stockBreakout Stocks Signals Backed By Experts - jammulinksnews.com
BMO Capital Reaffirms Buy Rating on Alnylam Pharma with $450 Price Target - AInvest
Alnylam Pharmaceuticals Sees Strong Sales of Rare Disease Drug, Raises Revenue Guidance - AInvest
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance - AOL.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam projects $2.65B–$2.8B 2025 revenue following AMVUTTRA ATTR-CM launch momentum - MSN
Why Is Alnylam Stock Gaining Friday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam soars past $50B market cap - The Business Journals
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - TradingView
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Call Transcript - Insider Monkey
Narrow-Moat Alnylam's Strong Launch of Amvuttra for ATTR-CM Drives Growth; Pipeline Makes Progress - Morningstar
Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace
Alnylam Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 292% - AInvest
Alnylam Pharmaceuticals Inc (ALNY) Q2 2025 Earnings Call Highlig - GuruFocus
Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam: Q2 Earnings Snapshot - Norwalk Hour
Alnylam Soars 15.43% on $1.31B Trade Volume Surge as TTR Revenues Jump 64% and Raised 2025 Outlook - AInvest
Amvuttra's stellar performance pushes Alnylam's guidance, stock higher - FirstWord Pharma
Alnylam Pharmaceuticals Surges 15.43% On Strong Technical Breakout - AInvest
Novartis wins FDA label update for Alnylam-partnered cholesterol drug - Seeking Alpha
Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches - insights.citeline.com
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast - inkl
Alnylam's Amvuttra: A Game-Changer in ATTR-CM and a Catalyst for Biotech Growth - AInvest
Alnylam: Amvuttra Is Just Getting Started (NASDAQ:ALNY) - Seeking Alpha
Alnylam reaches new highs on strong sales of closely watched rare disease drug - BioPharma Dive
Earnings call transcript: Alnylam’s Q2 2025 results boost stock by 18% - Investing.com Nigeria
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates - Investing.com
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals Surpasses Wall Street Expectations in Q2News and Statistics - IndexBox
Alnylam jumps on full year revenue guidance raise (ALNY) - Seeking Alpha
Alnylam Q2 2025 slides: ATTR-CM launch drives 64% revenue growth, guidance raised - Investing.com Canada
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alnylam Pharmaceuticals Skyrockets 12.3%—What’s Fueling This Biotech Surge? - AInvest
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):